Restenosis revisited

Circulation Research

Volumn 104, Issue 7, 2009, Pages 823-825

  Calvert, Patrick A ^a   Bennett, Martin R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Proliferation; Restenosis; Smooth muscle cell

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BETA LAPACHONE; CYCLIN D; CYCLIN E; PROTEIN P21; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; BETA-LAPACHONE; CARDIOVASCULAR AGENT; ENZYME ACTIVATOR; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; NQO1 PROTEIN, RAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

CAROTID ARTERY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVITY; FEMORAL ARTERY; GENE ACTIVATION; HUMAN; NONHUMAN; P53 GENE; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; TUMOR SUPPRESSOR GENE; VASCULAR SMOOTH MUSCLE; ANIMAL; CAROTID ARTERY OBSTRUCTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG ELUTING STENT; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; HYPERPLASIA; INTIMA; METABOLISM; NOTE; PATHOLOGY; RECURRENT DISEASE;

ANIMALS; CARDIOVASCULAR AGENTS; CAROTID STENOSIS; CELL PROLIFERATION; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; RECURRENCE; TUNICA INTIMA;

EID: 65249114852     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.196345     Document Type: Editorial

References (20)

1. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
2. Holmes DR Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, Windecker S, Krucoff MW. Thrombosis and drug-eluting stents: An objective appraisal. J Am Coll Cardiol. 2007;50:109-118.
3. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
4. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
5. Bennett MR, O'Sullivan M. Mechanisms of angioplasty and stent reste-nosis: Implications for design of rational therapy. Pharmacol Ther. 2001; 91:149-166.
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315-1323.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
9. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation. 2007; 115:2435-2441.
10. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-1058.
11. Kim S-Y, Jeoung NH, Oh CJ, Choi Y-K, Lee H-J, Kim H-J, Kim J-Y, Hwang JH, Tadi S, Yim Y-H, Lee K-U, Park K-G, Huh S, Min K-N, Jeong K-H, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M, Lee I-K. Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res. 2009;104:842-850.
12. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T, Taguchi T, Nakamaru K, Yano M, Kukidome D, Matsumoto K, Toyonaga T, Asano T, Nishikawa T, Araki E. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res. 2005;97:837-844.
13. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T, Hirata Y. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation. 2004;110:444-451.
14. O'Sullivan M, Scott S, McCarthy N, Shapiro LM, Kirkpatrick PJ, Bennett MR. Differential cyclin E expression in human in stent stenosis vascular smooth muscle cells identifies targets for selective anti-restenotic therapy. Cardiovasc Res. 2003;60:673-683.
15. de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis Trials. Curr Interv Cardiol Rep. 2000;2:326-331.
16. Rodriguez AE, Alemparte MR, Vigo CF, Pereira CF, Llaurado C, Russo M, Virmani R, Ambrose JA. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol. 2003;15: 581-584.
17. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB III, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106:1243-1250.
18. Hosoya T, Maruyama A, Kang MI, Kawatani Y, Shibata T, Uchida K, Warabi E, Noguchi N, Itoh K, Yamamoto M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothe-lial cells. J Biol Chem. 2005;280:27244-27250.
19. Fledderus JO, Boon RA, Volger OL, Hurttila H, Yla-Herttuala S, Pannekoek H, Levonen AL, Horrevoets AJ. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:1339-1346.
20. Chen XL, Varner SE, Rao AS, Grey JY, Thomas S, Cook CK, Wasserman MA, Medford RM, Jaiswal AK, Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothe-lial cells. A novel anti-inflammatory mechanism. J Biol Chem. 2003;278:703-711.